Extended release naltrexone vs buprenorphine
A recent randomized clinical noninferiority trial from Norway found that extended-release naltrexone was as noninferior to (and seemingly superior to) buprenorphine-naloxone in maintaining short-term abstinence from heroin (see doi:10.1001/jamapsychiatry.2017.3206). Details: --159 people were randomized to daily oral flexible-dose buprenorphine-naloxone (4-24 mg/d, target dose 16 mg/d) vs extended-release naltrexone 380mg intramuscularly every 4 weeks, for 12 weeks --mean age 36, 28% women, 90% white, 85% intravenous users, 3% HIV positive, 55% hepatitis C seropositive, approx 7 years of substance use --all patients went through an inpatient detox program (or were in prison/off drugs) for at least 7 days prior to starting the study --weekly drug testing Results: --mean daily dose of buprenorphine was 11 mg/d --105 people (66%) completed the study (attended all scheduled appointments, took meds as prescribed) --retention rate for naltrexone was non-inferior...